This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today

Dow Jones

01/16

ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.

The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.

The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.

Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603967590"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603967590\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603967590?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603967590","market":"us","top_or_hot":-1,"title":"This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today","media":"Dow Jones","content":"<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-16 19:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><head></head><body><p>ImmunityBio stock is on a tear in 2026 and it looks like the biotech company&#39;s stellar rally will keep going.</p><p>The shares are up 99% this year, as of Thursday close. In fact, they&#39;ve climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.</p><p>The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.</p><p>Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday&#39;s closing price.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603967590","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603967590","pubTimestamp":1768562891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"这只生物科技股今年上涨了100%。为什么今天又飙升了。——Barrons.com","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"ImmunityBio stock is on a tear in 2026 and it looks like the biotech company's stellar rally will keep going.The shares are up 99% this year, as of Thursday close. In fact, they've climbed on every trading day so far in 2026. The streak, and the impressive gain, are set to continue as the stock was pointing another 21% higher ahead of the open Friday.The catalysts also keep coming. The biotech company said full-year revenue from its bladder cancer drug ANKTIVA was set to surge 700% year-over-year to $113 million, in its preliminary earnings results Thursday. Earlier this week Immunitybio said the Saudi Food and Drug Authority has approved ANKTIVA for the treatment of patients with non-small cell lung cancer.Just five analysts cover the stock, according to FactSet data, but they have an average price target of $10.40, implying a 163% upside to Thursday's closing price.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}